Novel influenza A (H1N1) is a new flu virus of swine origin that was first detected in Mexico and the United States in March and April, 2009. The first novel H1N1 patient in the United States was confirmed by laboratory testing at CDC on April 15, 2009. The second patient was confirmed on April 17, 2009. It was quickly determined that the virus was spreading from person-to-person. On April 22, CDC activated its Emergency Operations Center to better coordinate the public health response. On April 26, 2009, the United States Government declared a public health emergency.
It’s thought that novel influenza A (H1N1) flu spreads in the same way that regular seasonal influenza viruses spread; mainly through the coughs and sneezes of people who are sick with the virus.
West Pharmaceutical Services, Inc. today announced its financial results for the second quarter of 2010.
Vical Incorporated today reported financial results for the three months and six months ended June 30, 2010. Revenues decreased to $2.1 million for the second quarter of 2010 from $4.0 million for the second quarter of 2009, primarily as a result of a $1.5 million milestone payment in 2009 from Merck & Co., Inc., based on Merck's ongoing Phase 1 clinical-stage development of an investigational cancer vaccine.
Severe cases of swine flu requiring intensive care are on the rise this week. This has prompted a warning for the vulnerable to be vaccinated. NSW Health Communicable Diseases Branch director Dr Jeremy McAnulty said that the cases appear to be caused by the flu strain that caused the 2009 pandemic.
Henry Schein, Inc., the largest provider of healthcare products and services to office-based practitioners, today reported record financial results for the quarter ended June 26, 2010.
The U.S. Food and Drug Administration announced today that it has approved vaccines for the 2010-2011 influenza season in the United States.
The U.S. Food and Drug Administration is warning consumers not to take Miracle Mineral Solution, an oral liquid solution also known as "Miracle Mineral Supplement" or "MMS." The product, when used as directed, produces an industrial bleach that can cause serious harm to health.
GlaxoSmithKline announced today that the U.S. Food and Drug Administration's (FDA) Center for Biologics Evaluation and Research (CBER) has released the first lots of FluLaval® [Influenza Virus Vaccine] allowing distribution in the U.S. to begin for the 2010-2011 flu season. GSK anticipates distribution of Fluarix® [Influenza Virus Vaccine] to follow in the next several weeks.
New research shows that individuals with mild H1N1 infection may go undetected using standard diagnostic criteria, according to a study in the August issue of the American Journal of Infection Control, the official publication of the Association for Professionals in Infection Control and Epidemiology, (APIC). The study concludes that coughing or other respiratory symptoms are more accurate in determining influenza infection than presence of a fever.
Life Technologies Corporation today announced results for its second quarter ending June 30, 2010. Non-GAAP revenue for the second quarter was $906 million, an increase of 8 percent over the $839 million reported for the second quarter of 2009. Excluding the impact of currency and prior acquisitions and divestitures, organic revenue for the quarter grew 6 percent over the same period in the previous year.
The best way to prevent the spread of disease in rural areas may be by targeting select popular hangouts, according to a new study by the Kansas State University EpiCenter research team.The team published "Efficient Mitigation Strategies for Epidemics in Rural Regions" in the July edition of the journal PLoS ONE. The study looks at mitigation strategies based on a contact network model developed using information collected from residents in Clay County, Kan.
Quidel Corporation, a leading provider of rapid diagnostic testing solutions, announced today financial results for the second quarter ended June 30, 2010.
BD, a leading global medical technology company, today reported quarterly revenues of $1.878 billion for the third fiscal quarter ended June 30, 2010, representing an increase of 3.2 percent from the prior-year period, or 3.9 percent on a foreign currency-neutral basis.
CVS Caremark Corporation, today announced revenues, operating profit, and net income for the three and six months ended June 30, 2010.
Aetna today announced second-quarter 2010 operating earnings of $450.2 million, or $1.05 per share, an increase of 54 percent over 2009. The increase was largely the result of a higher Commercial underwriting margin from favorable prior-period reserve development and improved underlying performance, partially offset by lower Commercial Insured membership.
Today Sartorius, a leading international process and laboratory technology provider, published its first-half results for 2010. Both the Biotechnology Division and the Mechatronics Division reported substantial gains in order intake and sales revenue. The two divisions expanded their business in all regions. Besides the continued strong development in the Biotechnology Division, the positive earnings contributed by the Mechatronics Division are especially encouraging, given that this division faced an exceptionally adverse business climate last year as a result of the global economic crisis.
Secretary of State Hillary Rodham Clinton arrived in Vietnam on Thursday to participate in the Association of Southeast Asian Nations (ASEAN) regional forum and to mark the 15th anniversary of the normalization of diplomatic relations between the U.S. and Vietnam, VOV News reports. According to the news service, this is Clinton's first visit to the country since she became secretary of state. During her trip, she will have meetings with Deputy Minister and Foreign Minister Pham Gia Khiem (7/22).
The Association for Molecular Pathology participated in the Food and Drug Administration Center for Devices and Radiological Health public meeting on the oversight of laboratory developed tests. Dr. Karen Mann, President of AMP, served on the second panel of the meeting titled, Clinical Laboratory Challenges. Additionally, Dr. Elaine Lyon, Chair of the AMP Professional Relations Committee, presented public comments. "AMP believes that LDTs are an essential and central component of medical practice," said Dr. Lyon, "Without LDTs, the practice of medicine that we know today would be severely reduced in scope."
NanoViricides, Inc. reports that the results of the evaluation of several of its nanoviricides anti-Ebola agents were presented July 17th at the Annual Meeting of the American Society for Virology, July 17-21, at Montana State University, Bozeman, MT. Dr. Corinne Scully delivered the presentation, which was entitled "Polymeric Micelle Nanomaterials as Antiviral Compounds For Ebola Virus Infection."
BioRadar UK Ltd. predicted one year ago the current severe Foot and Mouth Disease (FMD) outbreaks after recording an increase of the Replikin Count (ref. 1) of the FMD Virus (FMDV) to its highest level in 52 years. Based on these findings, a new synthetic Replikins Trans-Strain FMD Vaccine, called TransFMDV(TM), has been developed and is now available. The announcement was made at the recent Biorbis Conference on Vaccine Production and Manufacturing in Amsterdam, the Netherlands. The conference was attended by major pharmaceutical company executives to examine how vaccine production could be accelerated in view of the problem last year of responding "too little, too late" to the H1N1 influenza pandemic.
The Food and Drug Administration can promote progress toward personalized medicine by approaching the oversight of laboratory developed tests (LDTs) in a focused, flexible, and balanced way according to the American Clinical Laboratory Association (ACLA). ACLA, which represents the nation's leading clinical laboratories, says that the factors supporting this approach include the growing role that such tests play in clinical decision making, especially in the area of new advanced diagnostics that derive from the mapping of the human genome and help fulfill the promise of personalized medicine.
Terms
While we only use edited and approved content for Azthena
answers, it may on occasions provide incorrect responses.
Please confirm any data provided with the related suppliers or
authors. We do not provide medical advice, if you search for
medical information you must always consult a medical
professional before acting on any information provided.
Your questions, but not your email details will be shared with
OpenAI and retained for 30 days in accordance with their
privacy principles.
Please do not ask questions that use sensitive or confidential
information.
Read the full Terms & Conditions.